Number of shares available for future purchase (in shares) Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Future Purchase Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Future Purchase Commitments and contingencies Commitments and Contingencies [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Total remaining obligation Lessee, Operating Lease, Liability, to be Paid Subject to FDA approval of Zimura in GA Tranche Five [Member] Tranche Five Term loan, gross (amount drawn) Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Prepayment penalty thereafter Debt Instrument, Percentage Of Prepayment Penalty, Prepayment Occurs Occurs On Or After The Second Anniversary And Prior To The Third Anniversary Of The Closing Date Debt Instrument, Percentage Of Prepayment Penalty, Prepayment Occurs Occurs On Or After The Second Anniversary And Prior To The Third Anniversary Of The Closing Date Area of lease property Area of Real Estate Property Schedule of allocated stock-based compensation expense Schedule Of Compensation Cost For Share-based Payment Arrangements, Allocation Of Share-based Compensation Costs By Financial Statement Line [Table Text Block] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Financial Statement Line [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Debt Instrument [Axis] Debt Instrument [Axis] Prepayment penalty second year Debt Instrument, Percentage Of Prepayment Penalty, Prepayment Occurs On Or After The First Anniversary And Prior To The Second Anniversary Of The Closing Date Debt Instrument, Percentage Of Prepayment Penalty, Prepayment Occurs On Or After The First Anniversary And Prior To The Second Anniversary Of The Closing Date Aggregate principal amount (up to) Line of Credit Facility, Maximum Borrowing Capacity Amortization and accretion of term loan related costs Accretion (Amortization) Of Debt Related Cost Accretion (Amortization) Of Debt Related Cost Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Investing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] On Closing Date Tranche One [Member] Tranche One Financial Instruments [Domain] Financial Instruments [Domain] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation and other expense Depreciation Accrued research and development expenses Accrued Research and Development Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer) for research and development related activities. Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Interest expense for term loan Interest Expense, Debt, Excluding Amortization Capped interest rate per annum Debt Instrument, Interest Rate, Stated Percentage University of Florida Research Foundation (UFRF) University of Florida Research Foundation (UFRF) [Member] University of Florida Research Foundation (UFRF) [Member] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Primary Licensed Product Primary Licensed Product [Member] Primary Licensed Product [Member] Number of product candidates in preclinical development Number Of Product Candidates In Preclinical Development Number Of Product Candidates In Preclinical Development Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Equity Component [Domain] Equity Component [Domain] Operating Leases Lessee, Operating Leases [Text Block] Settlement to be paid Loss Contingency, Estimate of Possible Loss Litigation stay period (in days) Litigation Stay Period Litigation Stay Period Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Plan Name [Axis] Plan Name [Axis] Available for sale securities Fair Value Debt Securities, Available-for-Sale Supplemental disclosure of cash paid Supplemental Cash Flow Information [Abstract] Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Lease Contractual Term [Domain] Lease Contractual Term [Domain] DelSiTech DelSiTech [Member] DelSiTech [Member] Unrecognized compensation costs, net of estimated forfeitures Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Employee stock purchase plan Employee Stock [Member] Change in working capital Increase (Decrease) in Working Capital Increase (Decrease) in Working Capital Award Type [Axis] Award Type [Axis] Reduction in mean rate of growth Mean Growth Rate Increase (Decrease), Primary Analysis Mean Growth Rate Increase (Decrease), Primary Analysis Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Lease liability Operating Lease, Liability, Current Sustained delivery applications Sustained Delivery Applications [Member] Sustained Delivery Applications [Member] Purchase period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of for sale securities Debt Securities, Available-for-Sale [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Term loan, net Long-Term Debt, Excluding Current Maturities Termination notice period License Agreement, Termination Notice Period License Agreement, Termination Notice Period Total liabilities Liabilities Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Drawn down increments at company's election Debt Instrument, Drawn Down Increments Debt Instrument, Drawn Down Increments Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Option and Compensation Plans Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Net cash proceeds Proceeds From Equity Financing Proceeds From Equity Financing Issuance of common stock and pre-funded warrants through underwritten offering, net of issuance costs Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Accumulated other comprehensive income associated with unrealized gain on available for sale securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Reduction in mean rate of growth without using square root transformation Mean Growth Rate Increase (Decrease), Supportive Analysis Mean Growth Rate Increase (Decrease), Supportive Analysis Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Estimated useful live (in years) Property, Plant and Equipment, Useful Life Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Payments for license fees Payments For License Fees Payments for License Fees Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Loan and Security Agreement Debt Disclosure [Text Block] Asset Acquisition [Axis] Asset Acquisition [Axis] Product and Service [Domain] Product and Service [Domain] Operating Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Financial Instrument [Axis] Financial Instrument [Axis] Document Period End Date Document Period End Date Archemix Archemix Corp [Member] Represents information pertaining to Archemix Corp. Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Schedule of changes in accumulated other comprehensive income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product [Member] Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product [Member] Debt Disclosure [Abstract] Net loss per common share: Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] First indication First Indication [Member] First Indication [Member] Balance at beginning of period (in shares) Balance at end of period (in shares) Shares, Issued Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Interest Expense, Debt Interest Expense, Debt Milestone Events [Axis] Milestone Events [Axis] Information pertaining to milestone events. Amounts reclassified from accumulated other comprehensive income, net of tax Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Line of Credit Line of Credit [Member] Asset-backed securities Investments in asset-backed securities Asset-Backed Securities [Member] Loss before income tax benefit Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net Loss Per Common Share Earnings Per Share [Text Block] Schedule of weighted-average assumptions used to estimate grant date fair value of stock options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Award Type [Domain] Award Type [Domain] Expected weighted average period to recognize share-based compensation costs (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Proceeds from stock plans Proceeds from Stock Plans Financing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Registrant Name Entity Registrant Name Issuance of common stock and pre-funded warrants through underwritten offering, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues End term charges percentage Debt Instrument, End Term Charges Percentage Debt Instrument, End Term Charges Percentage Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Payment period License Agreement, Payment Due Period License Agreement, Payment Due Period Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Supranational securities Investments in supranational securities Supranational Securities [Member] Supranational Securities Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Maturity date no earlier than Long-Term Debt, Term Operating expenses: Operating Expenses [Abstract] Consolidation Consolidation, Policy [Policy Text Block] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Emerging Growth Company Entity Emerging Growth Company Restricted stock units, Outstanding, expected to vest (in shares) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Expected To Vest, Number Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Expected To Vest, Number Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Trading Symbol Trading Symbol Entity File Number Entity File Number Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Qualified Cash percent Debt Instrument, Covenant, Qualified Cash Waiver, Percent Debt Instrument, Covenant, Qualified Cash Waiver, Percent Research and development Research and Development Expense Awarded (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units Restricted Stock Units (RSUs) [Member] Vested and expected to vest, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Investments Cash and Cash Equivalents, Fair Value Disclosure Milestone Events [Domain] Milestone Events [Domain] Represents the types of milestone events. The Wall Street Journal prime rate Prime Rate [Member] Increase in number of shares available under the Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized 2019 Inducement Plan Two Thousand Nineteen Inducement Plan [Member] Two Thousand Nineteen Inducement Plan [Member] Achievement of specified commercial milestones Achievement Of Specified Commercial Milestones [Member] Represents information pertaining to the achievement of specified commercial milestones. Shares issued for license fees (in shares) Shares Issued For License Fees Shares Issued For License Fees Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Number of licensed products Number Of Licensed Products Number of Licensed Products “Interest expense” paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Basic (in usd per share) Net loss per share of common stock - basic (in usd per share) Earnings Per Share, Basic Proceeds from employee stock plan purchases Proceeds From Stock Options And Warrants Exercised The cash inflow from associated with the amount received from holders exercising their stock options and warrants. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cranbury office lease Cranbury Office Space Lease [Member] Cranbury Office Space Lease, Through End Of February 2024 [Member] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Entity Interactive Data Current Entity Interactive Data Current Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Basic and diluted net loss per common share calculation: Net Income (Loss) Attributable to Parent [Abstract] Investments in money market funds* Money Market Funds [Member] Accumulated Deficit Retained Earnings [Member] Unrecognized share-based compensation costs for option awards, net of estimated forfeitures Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Litigation Status [Domain] Litigation Status [Domain] Schedule of Commitments and Contingencies [Table] Schedule of Commitments and Contingencies [Table] Schedule of information pertaining to commitments and contingencies. Common Stock Common Stock [Member] Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current period changes in fair value before reclassifications, net of tax OCI, before Reclassifications, Net of Tax, Attributable to Parent Number of reporting segments Number of Reportable Segments Number of shares of common stock available for issuance under the Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Summary of outstanding shares of RSU awards Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Statement [Table] Statement [Table] Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Lease, extended term Lessee, Operating Lease, Renewal Term Document Quarterly Report Document Quarterly Report Current assets Assets, Current [Abstract] Lease liability, non-current Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Investments in money market funds Cash Equivalents, at Carrying Value Purchase of marketable securities Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Recurring basis Fair Value, Recurring [Member] Segment and Geographic Information Segment Reporting, Policy [Policy Text Block] Avacincaptad Pegol Avacincaptad Pegol [Member] Avacincaptad Pegol Interest income, net Interest Income (Expense), Nonoperating, Net Document Fiscal Year Focus Document Fiscal Year Focus Statement [Line Items] Statement [Line Items] Prepayment penalty prior first year Debt Instrument, Percentage Of Prepayment Penalty, Prepayment Occurs Prior To First Anniversary Of Closing Date Debt Instrument, Percentage Of Prepayment Penalty, Prepayment Occurs Prior To First Anniversary Of Closing Date Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Right-of-use asset, net Operating Lease, Right-of-Use Asset 2013 Plan Employee stock purchase plan Stock Incentive 2013 Plan [Member] Stock Incentive 2013 Plan Contingent consideration arrangements, maximum amount Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High Operating lease rent expense Operating Lease, Expense Vested and expected to vest, end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Local Phone Number Local Phone Number Wet AMD Product Wet AMD Product [Member] Wet AMD Product [Member] Patients in trial Number Of Patients In Trial Number Of Patients In Trial Summary of the stock option activity including weighted average exercise prices, options outstanding and exercisable Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Amount to be paid on achievement of milestone Amount To be Paid On Achievement of Milestone Represents the amount to be paid by the entity on achievement of various milestones. Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Litigation Status [Axis] Litigation Status [Axis] Prepaid expense and other assets Increase (Decrease) in Prepaid Expense and Other Assets Achievement of specified commercial sales milestones Achievement Of Specified Commercial Sales Milestones [Member] Achievement Of Specified Commercial Sales Milestones Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax benefit Income Tax Expense (Benefit) Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional paid-in capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Milestone 3 is achieved Tranche Four [Member] Tranche Four Weighted average estimated incremental borrowing rate Operating Lease, Weighted Average Estimated Incremental Borrowing Rate Operating Lease, Weighted Average Estimated Incremental Borrowing Rate Milestone 1 is achieved through December 15, 2022 Tranche Two [Member] Tranche Two Diluted (in shares) Weighted average common shares outstanding - dilutive (in shares) Weighted Average Number of Shares Outstanding, Diluted Expected term of options (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Contingent consideration arrangements, maximum amount (in shares) Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Shares Issuable, High Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Shares Issuable, High Debt issuance costs (legal and other administrative fees) Debt Issuance Costs, Gross Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current miniCEP290 miniCEP290 [Member] miniCEP290 [Member] Common stock—$0.001 par value, 200,000,000 shares authorized, 120,572,641 and 115,277,012 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Preferred Stock Preferred Stock [Member] Awarded (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of potentially dilutive securities that have been excluded from the computations of diluted weighted average common shares outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of assets and liabilities that are measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Beginning of period End of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Lenders option to invest in equity financing Debt Instrument, Lenders Option To Invest In Equity Financing Debt Instrument, Lenders Option To Invest In Equity Financing Inception 4 Inception 4 [Member] Inception 4 [Member] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities Liabilities, Current [Abstract] Proceeds from term loan Proceeds from Issuance of Long-Term Debt Common stock, shares issued (in shares) Common Stock, Shares, Issued Income Statement Location [Domain] Income Statement Location [Domain] License Agreement License Agreement Terms [Member] Fair Value Measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Concentration of Suppliers Concentration of Suppliers Policy, [Policy Text Block] Disclosure of accounting policy for concentration of suppliers. Amendment Flag Amendment Flag Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Covenant revenue from sale, maintained market capitalization Debt Instrument, Covenant, Revenue From Sale, Market Capitalization Maintained, Waiver Debt Instrument, Covenant, Revenue From Sale, Market Capitalization Maintained, Waiver Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status University Of Massachusetts (UMass) University Of Massachusetts (UMass) [Member] University Of Massachusetts (UMass) [Member] Counterparty Name [Axis] Counterparty Name [Axis] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Schedule of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property, Plant and Equipment, Net Cash paid from operating cash flows Operating Lease, Payments Income tax refunds received Proceeds from Income Tax Refunds Stock options Share-Based Payment Arrangement, Option [Member] Expected common stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Term loan, net Long-Term Debt Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other expense, net Other Nonoperating Income (Expense) Unrealized loss on available for sale securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares authorized (in shares) Common Stock, Shares Authorized Total operating expenses Operating Expenses Maximum Maximum [Member] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Settled Litigation Settled Litigation [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Smaller Reporting Company Entity Small Business Accumulated amortization of debt issuance costs Accumulated Amortization, Debt Issuance Costs Measurement Frequency [Domain] Measurement Frequency [Domain] Common stock issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period C5 Licensed Product C5 Licensed Products [Member] Represents information pertaining to C5 Licensed products as defined by the agreement. Income tax receivable Increase (Decrease) in Income Taxes Receivable University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) [Member] University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) [Member] Milestone 2 is achieved through September 30, 2023 Tranche Three [Member] Tranche Three Number of Shares Underlying Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Income Statement and Statement of Comprehensive Income [Abstract] [Abstract] Income Statement and Statement of Comprehensive Income [Abstract] Income Statement and Statement of Comprehensive Income [Abstract] Accretion of end of term charge Amortization of Debt Discount (Premium) Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Title of 12(b) Security Title of 12(b) Security Debt Instrument [Line Items] Debt Instrument [Line Items] Parsippany Office Lease Parsippany Office Lease [Member] Parsippany Office Lease [Member] Payment of term loan issuance costs Payments of Debt Issuance Costs Present value of lease liabilities Operating Lease, Liability Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Amortization of premium and discounts on investment securities Accretion (Amortization) of Discounts and Premiums, Investments Clinical and marketing approval milestones Asset Acquisition, Clinical And Marketing Approval Milestones Asset Acquisition, Clinical And Marketing Approval Milestones Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] U.S. Treasury securities Investments in U.S. Treasury securities US Treasury Securities [Member] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Accretion of end of term charge Debt Instrument, Unamortized Discount Business Nature of Operations [Text Block] Convertible Notes Convertible Notes Payable [Member] Entity Filer Category Entity Filer Category Proceeds from follow-on public offering, net Proceeds from Issuance of Common Stock Basic (in shares) Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Vested and exercisable, end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Preferred stock—$0.001 par value, 5,000,000 shares authorized, no shares issued or outstanding Preferred Stock, Value, Issued Accrued interest payable Increase (Decrease) in Interest Payable, Net Issuance of common stock under employee stock compensation plans and warrants Stock Issued During Period, Value, Issued for Services Restricted stock units Restricted stock units Restricted Stock [Member] Specified commercial sales milestones with respect to a licensed product Specified Commercial Sales Milestones Related to a Licensed Product [Member] Specified Commercial Sales Milestones Related to a Licensed Product [Member] Property and equipment Property, Plant and Equipment [Line Items] Schedule of Debt Schedule of Debt [Table Text Block] General and administrative General and Administrative Expense [Member] Debt Tranche [Domain] Debt Tranche [Domain] Debt Tranche [Domain] Cover [Abstract] Cover [Abstract] Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Adeno-Associated Virus Mediated Gene Therapy Program Adeno-Associated Virus Mediated Gene Therapy Program [Member] Adeno-Associated Virus Mediated Gene Therapy Program Leases Lessee, Leases [Policy Text Block] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Schedule of stock-based compensation by award type Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Weighted average grant-date fair value, Outstanding, expected to vest (in usd per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Grant Date Fair Value Represents the weighted average fair value of equity awards, other than options, that are expected to vest as of the reporting date. Interest-only payment, period Line of Credit Facility, Interest-Only Payment, Period Line of Credit Facility, Interest-Only Payment, Period Total liabilities and stockholders' equity Liabilities and Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Amortization of debt issuance costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Cash Cash Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] 2022 Term Loan 2022 Term Loan [Member] 2022 Term Loan [Member] Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Share-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Achievement of specified clinical and regulatory milestones Achievement Of Specified Clinical And Regulatory Milestones [Member] Represents information pertaining to the achievement of specified clinical and regulatory milestones. Accumulated Other Comprehensive Income (Loss) Comprehensive Income [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted (in usd per share) Net loss per share of common stock - diluted (in usd per share) Earnings Per Share, Diluted GA Product GA Product [Member] GA Product [Member] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock options outstanding Employee And Nonemployee Stock Option [Member] An arrangement whereby an employee and non-employees are entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits. Total current liabilities Liabilities, Current Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Contingent consideration arrangements, contingently issuable shares as a percentage of shares outstanding Asset Acquisition, Contingent Consideration Arrangements, Contingently Issuable Shares As A Percentage Of Shares Outstanding Asset Acquisition, Contingent Consideration Arrangements, Contingently Issuable Shares As A Percentage Of Shares Outstanding Issuance of common stock under employee stock compensation plans and warrants (in shares) Stock Issued During Period, Shares, Issued for Services Corporate debt securities Investments in corporate debt securities Corporate Debt Securities [Member] Vested and exercisable, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Schedule of maturity of operating lease liability Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Cash, Cash Equivalents and Available for Sale Securities Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block] Product and Service [Axis] Product and Service [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Number of initial shares reserved for issuance under the Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Second and third indication Second and Third Indication [Member] Second and Third Indication [Member] Other Licensed Product Other Licensed Product [Member] Other Licensed Product [Member] Accrued interest receivable Increase (Decrease) in Accrued Interest Receivable, Net BEST1 License Agreement BEST1 License Agreement [Member] BEST1 License Agreement [Member] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, and Short-term Investments [Abstract] Cash, Cash Equivalents, and Short-Term Investments [Abstract] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Research and Development Expense, Policy [Policy Text Block] Weighted Average Grant-Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Licensing and Commercialization Agreements Collaborative Arrangement Disclosure [Text Block] Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Available for Sale Securities Credit Loss, Financial Instrument [Policy Text Block] Share price calculation base, period (in days) Asset Acquisition, Milestone Payment Share Price Basis For Calculation, Trading Days Asset Acquisition, Milestone Payment Share Price Basis For Calculation, Trading Days City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value [Abstract] Supplemental disclosures of non-cash information related to investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Debt Tranche [Axis] Debt Tranche [Axis] Debt Tranche [Axis] Pre-funded warrants outstanding (in shares) Class of Warrant or Right, Outstanding Accrued research and development expenses Increase (Decrease) In Accrued Research And Development Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred. Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense Research and Development Expense [Member] Schedule of computation of basic and diluted net loss per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Achievement of specified clinical and development milestones Achievement Of Specified Clinical And Development Milestones [Member] Achievement Of Specified Clinical And Development Milestones Operating right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability RHO-adRP License Agreement RHO-adRP License Agreement [Member] RHO-adRP License Agreement [Member]